Regulator Approves DPYD Test for Australian Clinical Use
Southern Cross Diagnostics can now supply the Yourgene Insight DPYD assay in Australia for clinical diagnostic testing.
Updated on Nov. 11, 2026 in Biotech

Australia's Therapeutic Goods Administration has approved supply of the Yourgene Insight DPYD assay for clinical diagnostic use, with Southern Cross Diagnostics Pty authorised to market it. The assay previously launched as a Research Use Only product in May 2026.
Why it matters
The test identifies patients at increased risk of severe or potentially fatal toxicity when receiving 5-fluorouracil (5-FU) treatment. Clinical availability could allow laboratories to screen patients before treatment begins.
The assay detects 19 clinically relevant DPYD variants, and the company estimates an addressable market of 16,000 to 66,000 tests a year in Australia. At the current Medicare rate of about A$182 per test, the estimated reimbursed value is A$3m to A$12m annually, though laboratory uptake remains unconfirmed.
The players
Therapeutic Goods Administration (TGA)
The TGA is Australia's federal regulator responsible for assessing and approving therapeutic goods, including in vitro diagnostic devices, before they can be supplied in Australia.
Novacyt
Novacyt is a France-headquartered diagnostics company whose Southern Cross Diagnostics subsidiary will market and supply the assay in Australia.
Yourgene Health
Yourgene Health is a Manchester-based molecular diagnostics company that manufactures the Yourgene Insight DPYD assay.
The details
The Yourgene Insight DPYD assay is manufactured by Yourgene Health, based in Manchester, and holds certification under the European Union's In Vitro Diagnostic Regulation (IVDR), received in September 2026. The approval allows Southern Cross Diagnostics Pty, part of the Novacyt Group, to supply the assay for clinical diagnostic use in Australia.
Timeline
May 2026: Yourgene Insight DPYD assay launched as a Research Use Only product.
September 2026: The assay received IVDR certification.
11 November 2026: TGA approval for Australian clinical use announced.
Clinical Pathway
The approval places DPYD genotyping alongside established pre-treatment screening for 5-fluorouracil chemotherapy, moving the test from research use into routine Australian clinical diagnostics. It follows the IVDR certification the assay received in September 2026.
Patients starting 5-fluorouracil treatment may be screened for DPYD variants where laboratories adopt the test, which could identify those at higher risk of severe toxicity. Availability will depend on laboratory uptake and Medicare reimbursement arrangements.
The takeaway
Clinical availability of the Yourgene Insight DPYD assay in Australia could help clinicians identify patients at higher risk of severe 5-FU toxicity before treatment. Its practical impact will depend on how quickly laboratories adopt the test.
Further reading
For more on the science behind genetic testing, see Biotech coverage of diagnostic developments.










